Compare BWAY & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWAY | ENTA |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 450.8M | 374.6M |
| IPO Year | N/A | 2012 |
| Metric | BWAY | ENTA |
|---|---|---|
| Price | $13.57 | $13.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $13.25 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 173.9K | 132.8K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $102,814,000.00 |
| Revenue This Year | $309.69 | $7.76 |
| Revenue Next Year | $26.21 | N/A |
| P/E Ratio | $81.98 | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $7.84 | $4.09 |
| 52 Week High | $26.63 | $17.15 |
| Indicator | BWAY | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 50.86 |
| Support Level | $11.55 | $12.09 |
| Resistance Level | $13.63 | $13.76 |
| Average True Range (ATR) | 0.63 | 0.79 |
| MACD | 0.32 | 0.05 |
| Stochastic Oscillator | 68.64 | 71.83 |
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.